Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,609.78
(
0.13%
)
US TECH 100
29,751.20
(
0.14%
)
Dow Jones
51,307.79
(
0.45%
)
Brent Oil
95.26
(
-0.74%
)
Bitcoin
66,705.00
(
-6.53%
)
News Focus
News Focus
Post# of 448162
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Mellowmood77

Send PM Follow Ignore
Followers 26
Posts 665
Boards Moderated 0
Alias Born 04/30/2019

Mellowmood77

Re: dmlcento post# 203623

Thursday, 07/25/2019 5:47:07 PM

Thursday, July 25, 2019 5:47:07 PM

Post# of 448162
“In addition to assessing treatments’ clinical effectiveness, our reports also explore treatments’ economic value. And in this regard, our draft analysis currently suggests that Vascepa is highly cost-effective and fairly priced for the benefit it provides patients. “

I re-read this and it looks like the B+ rating is for clinical effectiveness and not cost effectiveness. The way it’s worded is the cost effectiveness of Vascepa is an A+?
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News